NEW YORK (GenomeWeb News) – Rosetta Genomics' first-half 2012 revenues saw a 14 percent drop year over year, the company reported after the close of the market on Friday.

During the first six months of the year, the Israel-based molecular diagnostics firm reported $51,000 in revenues, down from $59,000 a year ago.

Its R&D expenses were sliced to $740,000 from $1.9 million in H1 2011, while SG&A costs were lowered to $2.5 million $2.6 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.